|
| 37676819 | Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. | J Natl Cancer Inst | 2024 |
| 37980367 | Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). | Br J Cancer | 2024 |
| 36914848 | A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. | NPJ Precis Oncol | 2023 |
| 37289025 | The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. | Cancer Res | 2023 |
| 37250326 | A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer. | iScience | 2023 |
| 37207301 | Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. | Am Soc Clin Oncol Educ Book | 2023 |
| 37330052 | Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. | Ann Oncol | 2023 |
| 36996325 | Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2023 |
| 36437155 | IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer. | Urol Oncol | 2023 |
| 30528886 | Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy. | Urol Oncol | 2022 |
| 35507889 | Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. | JCO Precis Oncol | 2022 |
| 35859180 | Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. | Nature | 2022 |
| 35657159 | Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. | Prostate | 2022 |
| 35657158 | Genomic biomarkers to guide precision radiotherapy in prostate cancer. | Prostate | 2022 |
| 36439451 | Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation. | Front Oncol | 2022 |
| 36001857 | Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. | J Clin Oncol | 2022 |
| 36309516 | The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. | Nat Commun | 2022 |
| 36166584 | TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors. | Oncologist | 2022 |
| 36251389 | The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. | Cancer Res | 2022 |
| 35065838 | Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. | Eur Urol | 2022 |
| 34895867 | Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy. | Eur Urol Oncol | 2022 |
| 34812730 | Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. | Can Urol Assoc J | 2022 |
| 33414135 | <i>BRCA2</i>, <i>ATM</i>, and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. | Clin Cancer Res | 2021 |
| 33769071 | Olaparib for the treatment of metastatic prostate cancer. | Future Oncol | 2021 |
| 33742188 | Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer. | Nat Rev Urol | 2021 |
| 33836265 | Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. | Ann Oncol | 2021 |
| 33808193 | Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2021 |
| 33690902 | Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. | Cancer | 2021 |
| 33658587 | Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. | Sci Rep | 2021 |
| 33630412 | Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. | J Pathol Clin Res | 2021 |
| 34804843 | A marrow-minded look at immune checkpoint blockade resistance in metastatic castration resistant prostate cancer. | Transl Androl Urol | 2021 |
| 34801437 | Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. | Eur Urol Oncol | 2021 |
| 34219051 | Technical and biological constraints on ctDNA-based genotyping. | Trends Cancer | 2021 |
| 34171218 | The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre international retreat. | Can Urol Assoc J | 2021 |
| 34197212 | Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. | J Clin Oncol | 2021 |
| 34112710 | Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. | Clin Cancer Res | 2021 |
| 34258232 | Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. | Urol Case Rep | 2021 |
| 34083234 | Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. | Clin Cancer Res | 2021 |
| 33373705 | Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. | Urology | 2021 |
| 33452452 | Clinical implications of genomic alterations in metastatic prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 33422353 | Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. | Eur Urol | 2021 |
| 33420073 | Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. | Nat Commun | 2021 |
| 32451180 | Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. | Eur Urol | 2020 |
| 31640893 | Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. | Eur Urol | 2020 |
| 32046920 | Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. | Clin Genitourin Cancer | 2020 |
| 31744831 | Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. | Clin Cancer Res | 2020 |
| 32574722 | HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. | Ann Oncol | 2020 |
| 32847979 | Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. | Mol Cancer Ther | 2020 |
| 32724107 | Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. | Sci Rep | 2020 |
| 32218990 | Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer. | NPJ Genom Med | 2020 |